Literature DB >> 33480689

Bifunctional Doscadenamides Activate Quorum Sensing in Gram-Negative Bacteria and Synergize with TRAIL to Induce Apoptosis in Cancer Cells.

Xiao Liang1,2, Qi-Yin Chen1,2, Gustavo M Seabra1,2, Susan Matthew1, Jason C Kwan1, Chenglong Li1,2, Valerie J Paul3, Hendrik Luesch1,2.   

Abstract

New cyanobacteria-derived bifunctional analogues of doscadenamide A, a LasR-dependent quorum sensing (QS) activator in Pseudomonas aeruginosa, characterized by dual acylation of the pyrrolinone core structure and the pendant side chain primary amine to form an imide/amide hybrid are reported. The identities of doscadenamides B-J were confirmed through total synthesis and a strategic focused library with different acylation and unsaturation patterns was created. Key molecular interactions for binding with LasR and a functional response through mutation studies coupled with molecular docking were identified. The structure-activity relationships (SARs) were probed in various Gram-negative bacteria, including P. aeruginosa and Vibrio harveyi, indicating that the pyrrolinone-N acyl chain is critical for full agonist activity, while the other acyl chain is dispensable or can result in antagonist activity, depending on the bacterial system. Since homoserine lactone (HSL) quorum sensing activators have been shown to act in synergy with TRAIL to induce apoptosis in cancer cells, selected doscadenamides were tested in orthogonal eukaryotic screening systems. The most potent QS agonists, doscadenamides S10-S12, along with doscadenamides F and S4 with partial or complete saturation of the acyl side chains, exhibited the most pronounced synergistic effects with TRAIL in triple negative MDA-MB-231 breast cancer cells. The overall correlation of the SAR with respect to prokaryotic and eukaryotic targets may hint at coevolutionary processes and intriguing host-bacteria relationships. The doscadenamide scaffold represents a non-HSL template for combination therapy with TRAIL pathway stimulators.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33480689      PMCID: PMC8209783          DOI: 10.1021/acs.jnatprod.0c01003

Source DB:  PubMed          Journal:  J Nat Prod        ISSN: 0163-3864            Impact factor:   4.050


  47 in total

1.  Isolation, structure determination, and biological activity of Lyngbyabellin A from the marine cyanobacterium lyngbya majuscula.

Authors:  H Luesch; W Y Yoshida; R E Moore; V J Paul; S L Mooberry
Journal:  J Nat Prod       Date:  2000-05       Impact factor: 4.050

2.  Three parallel quorum-sensing systems regulate gene expression in Vibrio harveyi.

Authors:  Jennifer M Henke; Bonnie L Bassler
Journal:  J Bacteriol       Date:  2004-10       Impact factor: 3.490

3.  Sintokamides A to E, chlorinated peptides from the sponge Dysidea sp. that inhibit transactivation of the N-terminus of the androgen receptor in prostate cancer cells.

Authors:  Marianne D Sadar; David E Williams; Nasrin R Mawji; Brian O Patrick; Thamrin Wikanta; Ekowati Chasanah; Hari Eko Irianto; Rob Van Soest; Raymond J Andersen
Journal:  Org Lett       Date:  2008-10-04       Impact factor: 6.005

4.  Tannic Acid Inhibits Non-small Cell Lung Cancer (NSCLC) Stemness by Inducing G0/G1 Cell Cycle Arrest and Intrinsic Apoptosis.

Authors:  Nipin Sp; Dong Young Kang; Doh Hoon Kim; Ji-Seung Yoo; Eun Seong Jo; Alexis Rugamba; Kyoung-Jin Jang; Young Mok Yang
Journal:  Anticancer Res       Date:  2020-06       Impact factor: 2.480

5.  Dragonamides C and D, linear lipopeptides from the marine cyanobacterium brown Lyngbya polychroa.

Authors:  Sarath P Gunasekera; Cliff Ross; Valerie J Paul; Susan Matthew; Hendrik Luesch
Journal:  J Nat Prod       Date:  2008-04-05       Impact factor: 4.050

Review 6.  Therapeutic applications of TRAIL receptor agonists in cancer and beyond.

Authors:  Gustavo P Amarante-Mendes; Thomas S Griffith
Journal:  Pharmacol Ther       Date:  2015-09-05       Impact factor: 12.310

7.  Facilitating cytokine-mediated cancer cell death by proteobacterial N-acylhomoserine lactones.

Authors:  Vladimir Kravchenko; Amanda L Garner; John Mathison; Alim Seit-Nebi; Jing Yu; Irina P Gileva; Richard Ulevitch; Kim D Janda
Journal:  ACS Chem Biol       Date:  2013-03-21       Impact factor: 5.100

8.  Construction and analysis of luxCDABE-based plasmid sensors for investigating N-acyl homoserine lactone-mediated quorum sensing.

Authors:  M K Winson; S Swift; L Fish; J P Throup; F Jørgensen; S R Chhabra; B W Bycroft; P Williams; G S Stewart
Journal:  FEMS Microbiol Lett       Date:  1998-06-15       Impact factor: 2.742

Review 9.  Trailing TRAIL Resistance: Novel Targets for TRAIL Sensitization in Cancer Cells.

Authors:  Rachana Trivedi; Durga Prasad Mishra
Journal:  Front Oncol       Date:  2015-04-02       Impact factor: 6.244

10.  The novel TRAIL-receptor agonist APG350 exerts superior therapeutic activity in pancreatic cancer cells.

Authors:  Karen Legler; Charlotte Hauser; Jan-Hendrik Egberts; Anna Willms; Carola Heneweer; Susann Boretius; Christoph Röcken; Claus-Christian Glüer; Thomas Becker; Michael Kluge; Oliver Hill; Christian Gieffers; Harald Fricke; Holger Kalthoff; Johannes Lemke; Anna Trauzold
Journal:  Cell Death Dis       Date:  2018-05-01       Impact factor: 8.469

View more
  2 in total

Review 1.  Targeting regulated cell death (RCD) with small-molecule compounds in triple-negative breast cancer: a revisited perspective from molecular mechanisms to targeted therapies.

Authors:  Minru Liao; Rui Qin; Wei Huang; Hong-Ping Zhu; Fu Peng; Bo Han; Bo Liu
Journal:  J Hematol Oncol       Date:  2022-04-12       Impact factor: 17.388

2.  Metabolomic Characterization of a cf. Neolyngbya Cyanobacterium from the South China Sea Reveals Wenchangamide A, a Lipopeptide with In Vitro Apoptotic Potential in Colon Cancer Cells.

Authors:  Lijian Ding; Rinat Bar-Shalom; Dikla Aharonovich; Naoaki Kurisawa; Gaurav Patial; Shuang Li; Shan He; Xiaojun Yan; Arihiro Iwasaki; Kiyotake Suenaga; Chengcong Zhu; Haixi Luo; Fuli Tian; Fuad Fares; C Benjamin Naman; Tal Luzzatto-Knaan
Journal:  Mar Drugs       Date:  2021-07-16       Impact factor: 5.118

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.